Graybug Vision, Inc.

Every day, Graybug Vision works relentlessly to make healthy vision more accessible and more manageable for patients with chronic vision-threatening eye diseases. We are a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of chronic diseases of the retina and optic nerve. Our novel technologies are designed to release drugs in ocular tissue at a controlled rate for up to 12 months in order to improve patient compliance, reduce healthcare burdens and, ultimately, deliver better clinical outcomes.

Graybug Vision was founded in 2011 as a spin-out of the world-renowned Wilmer Eye Institute of the Johns Hopkins University School of Medicine. Based on Graybug's proprietary technologies, our R&D pipeline targets a range of chronic vision-threatening diseases, such as wet age-related macular degeneration and primary open angle glaucoma.

To learn more about who we are and what we solve for with our technologies and pipeline, please visit our website.